title: A standard, single dose of inhaled terbutaline attenuates hyperpnea-induced bronchoconstriction and mast cell activation in athletes.
abstract: Release of bronchoactive mediators from mast cells during exercise hyperpnea is a key factor in the pathophysiology of exercise-induced bronchoconstriction (EIB). Our aim was to investigate the effect of a standard, single dose of an inhaled β2-adrenoceptor agonist on mast cell activation in response to dry air hyperpnea in athletes with EIB. Twenty-seven athletes with EIB completed a randomized, double-blind, placebo-controlled, crossover study. Terbutaline (0.5 mg) or placebo was inhaled 15 min prior to 8 min of eucapnic voluntary hyperpnea (EVH) with dry air. Pre- and postbronchial challenge, urine samples were analyzed by enzyme immunoassay for 11β-prostaglandin F2α (11β-PGF2α). The maximum fall in forced expiratory volume in 1 s of 14 (12-20)% (median and interquartile range) following placebo was attenuated to 7 (5-9)% with the administration of terbutaline (P < 0.001). EVH caused a significant increase in 11β-PGF2α from 41 (27-57) ng/mmol creatinine at baseline to 58 (43-72) ng/mmol creatinine at its peak post-EVH following placebo (P = 0.002). The rise in 11β-PGF2α was inhibited with administration of terbutaline: 39 (28-44) ng/mmol creatinine at baseline vs. 40 (33-58) ng/mmol creatinine at its peak post-EVH (P = 0.118). These data provide novel in vivo evidence of mast cell stabilization following inhalation of a standard dose of terbutaline prior to bronchial provocation with EVH in athletes with EIB.
authors: Centre for Human Performance, Exercise and Rehabilitation, College of Health and Life Sciences, Brunel University London, United Kingdom;
authors: A J
authors: AJ
authors: Simpson
authors: Unit for Experimental Asthma Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Unit for Clinical Asthma Research, Department of Internal Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; and.
authors: J R
authors: JR
authors: Bood
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
authors: S D
authors: SD
authors: Anderson
authors: Centre for Human Performance, Exercise and Rehabilitation, College of Health and Life Sciences, Brunel University London, United Kingdom;
authors: L M
authors: LM
authors: Romer
authors: Unit for Clinical Asthma Research, Department of Internal Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; and.
authors: B
authors: B
authors: Dahlén
authors: Unit for Experimental Asthma Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; and.
authors: S-E
authors: SE
authors: Dahlén
authors: Centre for Human Performance, Exercise and Rehabilitation, College of Health and Life Sciences, Brunel University London, United Kingdom; pascale.kippelen@brunel.ac.uk.
authors: P
authors: 0000-0002-8443-0248
authors: P
authors: Kippelen
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage; D056352:Athletes; D001985:Bronchial Provocation Tests / Q000379:methods; D016084:Bronchoconstriction / Q000187:drug effects* / Q000502:physiology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006985:Hyperventilation / Q000503:physiopathology; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000502:physiology; D013726:Terbutaline / Q000008:administration & dosage*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D013726:Terbutaline
keywords: eucapnic voluntary hyperpnea; exercise-induced bronchoconstriction; inhaled β2-agonist; prostaglandin D2